We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-4.46%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$26.7M
Cap. Flow
+$49.5M
Cap. Flow %
18.91%
Top 10 Hldgs %
82.76%
Holding
28
New
6
Increased
13
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$13.5M
2
INZY
Inozyme Pharma
INZY
+$4.97M
3
NKTX icon
Nkarta
NKTX
+$4.7M
4
DTIL icon
Precision BioSciences
DTIL
+$4.69M
5
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$3.76M

Top Sells

Rank Stock Value
1
ONCR
Oncorus, Inc.
ONCR
+$67.9K

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Miscellaneous 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$47.2M 18.03%
1,671,976
+86,880
+5% +$2.52M
CGEM icon
2
Cullinan Oncology
CGEM
$1.45B
$39.1M 14.92%
3,047,609
+294,562
+11% +$3.34M
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$37M 14.14%
2,646,781
+65,684
+3% +$773K
PLRX icon
4
Pliant Therapeutics
PLRX
$71.2M
$24.9M 9.5%
3,106,807
+449,350
+17% +$2.88M
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$20.4M 7.8%
3,782,199
+697,889
+23% +$3.76M
KZR
6
DELISTED
Kezar Life Sciences
KZR
$15.2M 5.81%
184,079
+152,618
+485% +$13.5M
TSVT
7
DELISTED
2seventy bio
TSVT
$10.8M 4.13%
819,672
– –
INZY
8
DELISTED
Inozyme Pharma
INZY
$9.7M 3.71%
2,033,802
+1,141,745
+128% +$4.97M
CMPX icon
9
Compass Therapeutics
CMPX
$454M
$7.5M 2.86%
2,829,712
– –
IMA
10
ImageneBio Inc
IMA
$60.5M
$4.83M 1.85%
90,911
+23,015
+34% +$1.27M
DTIL icon
11
Precision BioSciences
DTIL
$232M
$4.81M 1.84%
100,125
+79,904
+395% +$4.69M
NKTX icon
12
Nkarta
NKTX
$197M
$4.41M 1.68%
+358,013
New +$4.7M
FRLN
13
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$4.23M 1.62%
324,155
– –
OMGA
14
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$4.01M 1.53%
1,055,882
– –
AKUS
15
DELISTED
Akouos Inc
AKUS
$3.92M 1.5%
836,120
– –
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.79M 1.45%
767,235
+278,600
+57% +$1.54M
ORTX
17
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.1M 1.18%
530,775
– –
ONCR
18
DELISTED
Oncorus, Inc.
ONCR
$2.98M 1.14%
2,367,436
-50,000
-2% -$67.9K
LRMR icon
19
Larimar Therapeutics
LRMR
$421M
$2.97M 1.13%
1,515,148
– –
KROS icon
20
Keros Therapeutics
KROS
$223M
$2.86M 1.09%
103,429
+41,200
+66% +$1.81M
CRVS icon
21
Corvus Pharmaceuticals
CRVS
$1.24B
$2.19M 0.84%
2,214,184
+511,047
+30% +$627K
TRDA icon
22
Entrada Therapeutics
TRDA
$283M
$1.99M 0.76%
+163,496
New +$1.24M
OVID icon
23
Ovid Therapeutics
OVID
$572M
$1.86M 0.71%
864,822
+11,934
+1% +$28.8K
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.2M 0.46%
+6,333
New +$1.28M
PHAS
25
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$450K 0.17%
+750,000
New +$718K
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, CHI Advisors held 28 positions worth $262M, up 11% from $235M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

CHI Advisors deployed $49.5M of net new capital in Q2 2022, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Nkarta: 358,013 shares worth $4.41M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Oncorus, Inc., an estimated $67.9K trimmed.

  • CHI Advisors's largest Q2 2022 buy was Nkarta: 358,013 shares worth $4.41M.
  • CHI Advisors added most to Kezar Life Sciences in Q2 2022, an estimated $13.5M increase.
  • CHI Advisors's biggest Q2 2022 reduction was Oncorus, Inc., cutting an estimated $67.9K.
  • CHI Advisors's ten largest holdings make up 83% of its $262M portfolio in Q2 2022.
  • CHI Advisors opened 6 new positions and closed 0 in Q2 2022.
  • CHI Advisors's portfolio value rose 11% quarter-over-quarter to $262M.

Based on CHI Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.